Imenorm 500 Tablet contains Imeglimin 500 mg, a novel oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus. Imeglimin acts through a unique mechanism targeting mitochondrial bioenergetics, improving insulin sensitivity and enhancing glucose-dependent insulin secretion. This dual action helps to reduce both fasting and postprandial blood glucose levels, contributing to better glycemic control. Imenorm 500 is typically prescribed as monotherapy or in combination with other antidiabetic agents when diet and exercise alone do not provide adequate glycemic control. The medication is well-tolerated with a favorable safety profile; common adverse effects may include mild gastrointestinal disturbances such as nausea or diarrhea, which are generally transient. Imeglimin does not cause significant hypoglycemia when used alone but caution is advised when combined with insulin or insulin secretagogues. Dosage should be individualized based on patient response and renal function, with adjustments recommended in cases of renal impairment. Regular monitoring of blood glucose levels and renal function tests is advised during therapy. Imenorm 500 offers a promising therapeutic option for patients requiring improved glycemic management with a novel mechanism of action.